Exelixis Inc. Stock
Price
Target price
€33.18
€33.18
0.150%
0.05
0.150%
€39.62
25.09.25 / Tradegate
WKN: 936718 / Symbol: EXEL / Name: Exelixis / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Exelixis Inc. Stock
The Exelixis Inc. stock is trending slightly upwards today, with an increase of €0.050 (0.150%) compared to yesterday's price.
With 45 Buy predictions and not a single Sell prediction Exelixis Inc. is an absolute favorite of our community.
With a target price of 39 € there is a slightly positive potential of 17.54% for Exelixis Inc. compared to the current price of 33.18 €.
So far the community has only identified positive things for Exelixis Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Exelixis Inc. in the next few years
Pros
?
B****
?
M***** P*******
?
S********** s********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Exelixis Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Exelixis Inc. | 0.150% | -2.812% | 0.698% | 41.071% | 1.654% | 100.775% | 61.854% |
| Ironwood Pharmaceuticals | -6.960% | -11.570% | 1.905% | -69.944% | -74.524% | -89.715% | -86.790% |
| Novocure Ltd | 0.500% | -0.181% | 8.268% | -21.457% | -62.225% | -85.447% | -88.043% |
| Iovance Biotherapeutics Inc. | 2.940% | 2.790% | -14.392% | -78.283% | -73.962% | -81.973% | -93.429% |
Comments
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at Morgan Stanley from $46.00 to $50.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $47.00 price target on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Show more
Ratings data for EXEL provided by MarketBeat
News
Exelixis Stock: Mixed Signals After Earnings Beat
Biotech company Exelixis delivered notably mixed second-quarter 2025 results, creating divergent investor reactions. The California-based firm reported earnings per share of $0.75, significantly
Exelixis Q2 Revenue Falls 11 Percent
Exelixis (NASDAQ:EXEL), an oncology-focused biotech, reported results for Q2 2025 on July 28, 2025. For the period, the company delivered non-GAAP earnings per share (EPS) of $0.75 in Q2 FY2025
Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner
A decade ago, shares of Exelixis (NASDAQ: EXEL), a biotech company specializing in oncology, were trading for under $10 per share. Today, the drugmaker's shares are changing hands for about $45